CureVac NV
NASDAQ:CVAC

Watchlist Manager
CureVac NV Logo
CureVac NV
NASDAQ:CVAC
Watchlist
Price: 2.66 USD 3.91% Market Closed
Market Cap: 596.7m USD
Have any thoughts about
CureVac NV?
Write Note

CureVac NV
Total Assets

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

CureVac NV
Total Assets Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Assets CAGR 3Y CAGR 5Y CAGR 10Y
CureVac NV
NASDAQ:CVAC
Total Assets
€788.2m
CAGR 3-Years
-20%
CAGR 5-Years
44%
CAGR 10-Years
N/A
BioNTech SE
NASDAQ:BNTX
Total Assets
€23B
CAGR 3-Years
115%
CAGR 5-Years
104%
CAGR 10-Years
N/A
MorphoSys AG
XETRA:MOR
Total Assets
€1.8B
CAGR 3-Years
4%
CAGR 5-Years
27%
CAGR 10-Years
15%
Immatics NV
NASDAQ:IMTX
Total Assets
€510m
CAGR 3-Years
26%
CAGR 5-Years
32%
CAGR 10-Years
N/A
Biotest AG
XETRA:BIO
Total Assets
€1.3B
CAGR 3-Years
6%
CAGR 5-Years
4%
CAGR 10-Years
4%
Formycon AG
XETRA:FYB
Total Assets
€890.4m
CAGR 3-Years
123%
CAGR 5-Years
86%
CAGR 10-Years
N/A
No Stocks Found

CureVac NV
Glance View

Market Cap
596.7m USD
Industry
Biotechnology

CureVac BV is a clinical-stage biopharmaceutical company, which engages in developing transformative medicines based on messenger ribonucleic acid (mRNA). The company is headquartered in Tuebingen, Baden-Wuerttemberg and currently employs 500 full-time employees. The company went IPO on 2020-08-14. The firm is engaged in the therapeutic development of messenger Ribonucleic Acid (mRNA) and RNA-based vaccines. CureVac AG focuses on developing vaccines for infectious diseases and drugs to treat cancer and rare diseases. The firm's pipeline focuses on three areas: cancer immunotherapy, prophylactic vaccines, and protein-based therapies.

CVAC Intrinsic Value
5.16 USD
Undervaluation 48%
Intrinsic Value
Price

See Also

What is CureVac NV's Total Assets?
Total Assets
788.2m EUR

Based on the financial report for Dec 31, 2023, CureVac NV's Total Assets amounts to 788.2m EUR.

What is CureVac NV's Total Assets growth rate?
Total Assets CAGR 5Y
44%

Over the last year, the Total Assets growth was -8%. The average annual Total Assets growth rates for CureVac NV have been -20% over the past three years , 44% over the past five years .

Back to Top